Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate

Pediatric Critical Care Medicine

Volumn 8, Issue 1, 2007, Pages 61-63

  Lechner, Evelyn ^a   Moosbauer, Werner ^a   Pinter, Miklos ^a   Mair, Rudolf ^a   Tulzer, Gerald ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALBUMIN; CALCIUM SENSITIZER; DOBUTAMINE; DOPAMINE; FENTANYL; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; MIDAZOLAM; MILRINONE;

ABSENCE OF SIDE EFFECTS; ARTERIAL PRESSURE; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY BLOOD FLOW; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FOLLOW UP; FORWARD HEART FAILURE; GESTATIONAL AGE; GREAT VESSELS TRANSPOSITION; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; HYPERTROPHIC PYLORUS STENOSIS; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; MALE; NEWBORN; POSTOPERATIVE COMPLICATION; PREMATURITY; PRIORITY JOURNAL; STUNNED HEART MUSCLE; SURGICAL TECHNIQUE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TWINS;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; GESTATIONAL AGE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, PEDIATRIC; MALE; MYOCARDIAL STUNNING; POSTOPERATIVE COMPLICATIONS; PYRIDAZINES; TIME FACTORS; TRANSPOSITION OF GREAT VESSELS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 33846488971     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000253026.67341.5D     Document Type: Article

References (10)

1. 2+-sensitization. Eur J Pharmacol 2004; 486:1-8
2. Antila S, Pesonen U, Lehtonen L, et al: Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 2004; 23:213-222
3. Slawsky MT, Colucci WS, Gottlieb SS, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102:2222-2227
4. Kivikko M, Lehtonen L, Colucci W: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107:81-86
5. Follath F, Cleland JGF, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomized double-blind trial. Lancet 2002; 360:196-202
6. Moiseyev VS, Poder P, Andrejevs N, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432
7. Michaelis AD, McKeown B, Kostal M, et al: Effects of intravenous levosimendan on human coronary vasomotor regulation. Left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111:1504-1509
8. Booker PD: Myocardial stunning in the neonate. Br J Anaesth 1998; 80:371-383
9. Namachivayam P, Crossland DS, Butt WW, et al: Early experience with levosimendan in children with ventricular dysfunction. Pediatr Crit Care Med 2006; 7:445-448
10. Turanlahti M, Boldt T, Palkama T, et al: Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5:457-462